Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Female Contraception - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H1 2017, provides an overview of the Female Contraception (Women's Health) pipeline landscape. Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones). Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 6, 3, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively. Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health). - The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Female Contraception - Overview Female Contraception - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Female Contraception - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Female Contraception - Companies Involved in Therapeutics Development Addex Therapeutics Ltd Agile Therapeutics Inc Bayer AG Evofem Inc Hervana Ltd Mithra Pharmaceuticals SA Orbis Biosciences Inc Teva Pharmaceutical Industries Ltd Viramal Ltd Female Contraception - Drug Profiles (anastrozole + levonorgestrel) - Drug Profile Product Description Mechanism Of Action R&D Progress (dienogest + ethinyl estradiol) PR - Drug Profile Product Description Mechanism Of Action R&D Progress (drospirenone + estetrol) - Drug Profile Product Description Mechanism Of Action R&D Progress (estradiol acetate + segesterone acetate) - Drug Profile Product Description Mechanism Of Action R&D Progress ADX-68693 - Drug Profile Product Description Mechanism Of Action R&D Progress AG-200 ER - Drug Profile Product Description Mechanism Of Action R&D Progress AG-200 SP - Drug Profile Product Description Mechanism Of Action R&D Progress AG-20015 - Drug Profile Product Description Mechanism Of Action R&D Progress AG-890 - Drug Profile Product Description Mechanism Of Action R&D Progress Amphora - Drug Profile Product Description Mechanism Of Action R&D Progress BAY-1007626 - Drug Profile Product Description Mechanism Of Action R&D Progress drospirenone - Drug Profile Product Description Mechanism Of Action R&D Progress Drug for Female Contraception - Drug Profile Product Description Mechanism Of Action R&D Progress EC-508 - Drug Profile Product Description Mechanism Of Action R&D Progress Estetrol - Drug Profile Product Description Mechanism Of Action R&D Progress etonogestrel ER - Drug Profile Product Description Mechanism Of Action R&D Progress EVE-106 - Drug Profile Product Description Mechanism Of Action R&D Progress LJ-102 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody Conjugates for Female Contraception - Drug Profile Product Description Mechanism Of Action R&D Progress NOV-1003 - Drug Profile Product Description Mechanism Of Action R&D Progress PPCM - Drug Profile Product Description Mechanism Of Action R&D Progress S-003296 - Drug Profile Product Description Mechanism Of Action R&D Progress S-0101255 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule 2 for Fertility Control - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Female Contraception - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target Progesterone Receptor for Fertility Control - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides for Female Contraception - Drug Profile Product Description Mechanism Of Action R&D Progress TV-46046 - Drug Profile Product Description Mechanism Of Action R&D Progress Female Contraception - Dormant Projects Female Contraception - Discontinued Products Female Contraception - Product Development Milestones Featured News & Press Releases Jun 27, 2017: Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study May 12, 2017: Mithra to Initiate PK Study for Estelle May 06, 2017: Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla at ACOG 2017 May 03, 2017: Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists Apr 27, 2017: Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Womens Health Apr 11, 2017: Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA Mar 16, 2017: Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference Feb 07, 2017: Mithra Completes Recruitment For European Phase III Estelle Study Jan 18, 2017: Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive Nov 07, 2016: Agile Therapeutics Announces Completion of Subject Visits for Twirla Phase 3 SECURE Clinical Trial Sep 23, 2016: Mithra Pharmaceuticals: Phase III Clinical Study for Estelle in US Launched with first Randomized Patient Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68693 Jul 22, 2016: Green Light From FDA For The Launch Of Estelle (E4/Drsp) Phase III Study In The United States Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Female Contraception, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Female Contraception - Pipeline by Addex Therapeutics Ltd, H1 2017 Female Contraception - Pipeline by Agile Therapeutics Inc, H1 2017 Female Contraception - Pipeline by Bayer AG, H1 2017 Female Contraception - Pipeline by Evofem Inc, H1 2017 Female Contraception - Pipeline by Hervana Ltd, H1 2017 Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H1 2017 Female Contraception - Pipeline by Orbis Biosciences Inc, H1 2017 Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 Female Contraception - Pipeline by Viramal Ltd, H1 2017 Female Contraception - Dormant Projects, H1 2017 Female Contraception - Dormant Projects, H1 2017 (Contd..1), H1 2017 Female Contraception - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
